BCG is indicated for intravesical immunotherapy of non–muscle-invasive bladder cancer (NMIBC) with intermediate- or high-risk of recurrence and/or progression, including carcinoma in situ; see the tables on recurrence risk (Abre numa nova janela) and progression risk (Abre numa nova janela).
https://www.urology-textbook.com/bcg-intravesical.html (Abre numa nova janela)
Data
17/11/2025
0 comentários
Gostaria de ser o primeiro a escrever um comentário?
Torne-se membro de urology-textbook.com e comece a conversa.
